Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
In a strategic move to revolutionize cell therapy manufacturing, Cellular Origins has acquired the Actia Platform intellectual property (IP). This acquisition aims to bolster Cellular Origins' capabilities in automate...
Share This Article
Ready-to-post copy includes the article link.
Cellular Origins acquires Actia Platform IP to improve automated cell therapy manufacturing. In a strategic move to revolutionize cell therapy manufacturing, Cellular Origins has acquired the Actia Platform intellectual property (IP). This acquisition aims to bolster Cellular Origins' capabilities in automate... Read the full IIPLA article: https://iipla.org/news/cellular-origins-acquires-actia-platform-ip-to-improve-automated-cell-therapy-manufacturing